SeekingAlpha · Sep 30, 2026
PH
NASDAQ · PHAR
Pharming Group N.V.
Healthcare · Biotechnology
$9.79
Up+$0.26 (+2.73%)
Updated Oct 11, 2026, 2:47 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.2B
- P/E ratio
- 3,147.1
- Dividend yield
- 0.00%
- 52-week range
- $9.44 – $18.41
- Volume
- 3.33K
- Avg. volume
- 16.7K
Price performance · PHAR
PHAR price history
1M range · 0 trading sessions · Daily adjusted prices
PHAR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PHAR news
The latest Smart Investors Daily articles mentioning PHAR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PHAR research
Overview
Company profile and research snapshot.
Company profile
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $42.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Sep 22, 2026 | JEFFERIES | Buy | — |
| Jul 30, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| Jul 13, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Pharming announces CEO transition
Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kennet
Yahoo · Sep 25, 2026
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration
Benzinga · Sep 22, 2026
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
